Health · Pharma & Biotech · 1 hr ago
Brazil approves two more semaglutide injection pens
Brazil’s Anvisa registered two new semaglutide injection pens on Tuesday, bringing the number of approved GLP-1 pens in the country in 2026 to 22.
The products are an unnamed generic and a similar medicine called Loryvia, registered for Ávita Care Importação e Distribuição de Produtos.
Both are based on Owozy, whose reference product is Ozempic, and are approved for adults with inadequately controlled type 2 diabetes.
Semaglutide acts like the gut hormone GLP-1 and can increase fullness by slowing stomach emptying.
The approvals come after semaglutide’s patent expired in March 2026, opening the market to more versions of the medicine.
There is no announced pharmacy launch date or price, and the medicines require a prescription.
Brazil’s health regulator approved two more injectable semaglutide products, a generic and a similar medicine called Loryvia.
The decision was published in the Official Gazette on November 10.
Both products are based on Owozy and were registered to Ávita Care Importação e Distribuição de Produtos Ltda.
They are indicated for adults with inadequately controlled type 2 diabetes.
There is no stated date for their arrival in pharmacies, and their prices have not been announced.
- Who
- Brazil’s National Health Surveillance Agency (Anvisa) approved the products.
- What
- It approved a generic semaglutide product and Loryvia, a similar medicine.
- When
- The decision was published on November 10, 2026.
- Where
- Brazil.
- Why
- They are indicated for adults with inadequately controlled type 2 diabetes.
This story does not have two clearly opposing sides.
The patent for semaglutide fell, according to the article.
Anvisa approved five medicines at once.
Anvisa registered the first oral semaglutide medicine.
The decision approving the generic and Loryvia was published in the Official Gazette.
- New products
- Generic semaglutide and Loryvia
- Active ingredient strength
- 1.34 mg/mL
- Registration holder
- Ávita Care Importação e Distribuição de Produtos Ltda.
- Indication
- Adults with inadequately controlled type 2 diabetes
- GLP-1 injection pens approved in Brazil in 2026
- 22